Getting a peptide drug through clinical trials is one challenge. Getting it manufactured reliably at a commercial scale is a different problem entirely.
The peptide therapeutics market is projected to nearly double by 2033, crossing USD 294 billion from USD 140 billion in 2025. That kind of growth puts enormous pressure on manufacturing infrastructure. Programs that worked at the kilogram scale start showing cracks at 10 kg, 50 kg, or 100 kg. The decisions made early in development either absorb that pressure or buckle under it.
Choosing the right CDMO for peptide manufacturing is one of the most consequential decisions a pharma or biotech team will make. This article covers what that decision actually involves.
From Lab Success to Commercial Failure: Why Scale-Up Breaks Down
Most peptide programs do not fail because the chemistry is wrong. They fail because the chemistry was never designed with scale in mind.
Solid-phase peptide synthesis (SPPS) is the dominant route for therapeutic peptides. At the lab scale, it is manageable. At a commercial scale, the same process looks very different. According to a 2024 industry assessment of 40 peptide manufacturing processes, the average process mass intensity (PMI) for SPPS is approximately 13,000, compared to a median of 168 to 308 for small molecules. That gap in solvent and reagent demand does not shrink at scale. It compounds.
Common failure points when moving from clinical to commercial volumes include:
- Resin swelling and mixing dynamics that behave differently in large reactors
- Temperature gradients that shift epimerization rates and side reaction profiles
- Preparative chromatography columns that lose resolution and loadability at commercial volumes
- Impurity profiles that change as batch size increases, requiring re-validation of analytical methods
The programs that make this transition cleanly are the ones that anticipated these issues during process development, not after the first failed commercial batch.
Synthesis Route Selection Shapes Everything Downstream
One of the most important and most underestimated scale-up decisions is route selection. SPPS, liquid phase peptide synthesis (LPPS), and hybrid approaches are not interchangeable. Each carries different cost, yield, and impurity implications that become more pronounced as volume increases.
For shorter peptides, LPPS often delivers better yield and lower solvent consumption at scale. For longer or more structurally complex sequences, hybrid strategies allow fragment condensation that reduces cumulative failure modes. Defaulting to SPPS because it is familiar is a process risk, not a safe choice.
A capable CDMO for peptide manufacturing evaluates route selection based on sequence complexity, target scale, and downstream purification demands before a single gram is synthesized. That upfront analysis is what separates programs that scale predictably from those that require expensive rework mid-development.
Purification at Scale Is a Cost and Quality Problem Simultaneously
Synthesis and purification are often treated as sequential steps. At a commercial scale, they are deeply interdependent.
Peptide impurities are not generic contaminants. Deletion sequences, epimers, and oxidation variants are structurally near-identical to the target molecule. Standard reverse-phase HPLC often cannot resolve them without orthogonal methods. At commercial volumes, this creates two converging problems:
- Purification complexity drives up cost, with preparative chromatography becoming the largest single cost driver in the peptide production process
- Counterion management adds process steps, as TFA carryover from SPPS requires exchange to pharmaceutically acceptable salt forms before final drug substance release
The right CDMO for peptide manufacturing designs a purification strategy in parallel with synthesis, not after it. When purification is treated as a downstream fix for synthesis problems, the costs and timelines grow fast.
Regulatory Readiness Cannot Be Retrofitted
The EMA’s dedicated synthetic peptide guideline becomes legally effective June 1, 2026. It covers manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, and comparability requirements. FDA expectations on impurity profiling for ANDA submissions are tightening in parallel.
Neither framework was written with generic API manufacturing in mind. Sponsors moving a peptide program toward commercial supply need CMC documentation that reflects peptide-specific risks from the start. Drug Master File preparation, impurity profiling aligned to current guidance, and filing support structured around comparability after process changes are not tasks to outsource at the last minute.
A CDMO for peptide manufacturing that has worked through EMA and FDA filings on peptide programs brings practical knowledge of what reviewers expect. That experience shortens review cycles and reduces the risk of complete response letters driven by CMC deficiencies.
What Strong Commercial-Scale Infrastructure Actually Looks Like
Purpose-built capacity matters. Reactor volume, solvent handling systems, downstream preparative HPLC systems, lyophilization capacity, and waste management processes all require scale-specific engineering.
When evaluating a CDMO for peptide manufacturing at a commercial scale, the questions worth asking are:
- What is the maximum batch size with validated yield and purity data?
- Has the CDMO demonstrated downstream scalability for purification, not just synthesis?
- What in-process controls are in place to catch coupling failures before they compound?
- How does the CDMO manage the transition from development batches to GMP production?
Answers supported by batch data, not capability claims, are what matter.
Where Neuland Laboratories Fits in This Picture
Neuland Laboratories has built its peptide capabilities to address exactly the challenges that commercial-scale programs encounter.
With expertise across SPPS, LPPS, and hybrid synthesis strategies, three US FDA and EMA-approved cGMP facilities, and a newly operational commercial peptide manufacturing facility at its Bonthapally campus, Neuland supports programs from early process development through multi-kilogram commercial supply.
The company supplies over 150 peptide building blocks to global vendors and innovator companies, and its analytical and regulatory teams are experienced in preparing CMC documentation for both FDA and EMA submissions.
For pharma and biotech teams planning the commercial supply transition for a peptide program, Neuland’s depth in both process chemistry and regulatory support makes it a credible partner for programs where execution risk is high.
Get in touch with Neuland’s team to discuss your peptide manufacturing requirements.
FAQs
1. When is the right time to engage a CDMO for commercial peptide scale-up?
The earlier, the better. Engaging a commercial-scale CDMO during late clinical development, ideally Phase II, allows process development and purification strategy to be validated against commercial targets before the program is under regulatory timelines. Starting at Phase III or post-approval creates process transfer risk and can delay commercial launch.
2. What is the biggest technical risk in scaling peptide manufacturing?
Purification is consistently the highest-risk step. Impurity profiles that are manageable at a small scale become commercially disqualifying if they cannot be resolved by preparative chromatography at batch volumes. Designing the purification strategy against the commercial impurity profile, rather than the lab-scale crude purity, is the key mitigation.
3. How does the synthesis route affect commercial manufacturing cost?
Significantly. SPPS carries high solvent and reagent intensity, which drives the cost of goods and waste handling at scale. Evaluating LPPS or hybrid strategies early in development, particularly for shorter or modular peptide sequences, can reduce commercial manufacturing costs substantially without compromising quality.
Leave a Comment